

ASX ANNOUNCEMENT**CARDIOCEL[®] SALES UPDATE – 1st SALES ORDERS FOR THE US**

- Admedus gets first sales orders in the US market
- Launched in Europe with key centres targeted
- CardioCel[®] on show at AATS conference in Toronto this month

Brisbane, Australia, 7th May 2014

Admedus (ASX: AHZ) today announced further progress on the launch of CardioCel[®], including the first sales orders for the product in the US market. The initial US sales orders are ahead of the expected mid-year timing the Company previously forecast. The focus for our team now will be to get CardioCel[®] used in key centres across Europe and the US.

“This is an important milestone for the Company as we look to grow our revenue over the coming 12 months and beyond” said Admedus CEO Mr. Lee Rodne “we are aiming for CardioCel[®] to be in use in 15 key centres in Europe and the US over the next 12 months, which will provide us with a significant presence in the market.”

US

Admedus has now received the first sales orders for CardioCel[®] in the US market. The Company presented CardioCel[®] to US cardio-thoracic surgeons during the recent American Association of Thoracic Surgeons (AATS) conference in Toronto. The sales team have been working with US based cardio-thoracic surgeons, communicating the benefits of CardioCel[®] and its advantages over existing products on the market.

Europe

In Europe, Admedus officially launched CardioCel[®] late in 2013, with the aim of introducing it into 15 key cardio-thoracic centres. To date, CardioCel[®] has been used in 8 of the target centres in Europe and the Company expects several more to come on stream by mid-year, which is on par with our initial expectations. Surgeons who have used CardioCel[®] in surgical procedures have not reported any issues.

Rest of the World

Admedus is currently seeking approval in a number of other jurisdictions to meet its global launch plans. CardioCel[®] continues to be used in Australia under the Authorised Prescriber Scheme with over 100 patients implanted.

For more information, please contact:

Dr. Julian Chick, Chief Operating Officer Admedus Limited Tel: +61 3 9620 5454

Media:

Tahlia Weston

Buchan Consulting

+61 3 8866 1203

tweston@buchanwe.com.au

About Admedus Limited

Admedus (ASX: AHZ) is a diversified healthcare company focused on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow its product and service offerings and expanding revenues from its existing profitable medical sales and distribution business. The Company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus is in the process of commercialising its innovative tissue engineering technology for regenerative medicine. Admedus also has a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential such as Herpes and Human Papillomavirus.

Further information on the Company can be found on www.admedus.com

Admedus Regen

Admedus Regen started as a research programme in 2001 focusing on tissue engineering and regenerative medicine based around the proprietary ADAPT[®] Tissue Engineering Process. The lead programme, CardioCel[®] is approved in Europe and is being used in Australia under the Authorised Prescriber Scheme. CardioCel[®] is a cardiovascular scaffold used to repair paediatric and adult heart deformities. These deformities range from routine "hole in the heart" operations to major vessel outflow tract repairs. The CardioCel[®] scaffold may also be used to repair leaking heart valves in paediatric and adult patients. CardioCel[®] has been shown to allow tissue regeneration once implanted. Some researchers postulate that stem cells play an active role in tissue regeneration*, suggesting that CardioCel[®] facilitates endogenous stem cells and other cells to regenerate and repair damaged tissue.

The division is based on the patented ADAPT[®] Tissue Engineering Process as a platform technology to produce implantable tissue scaffolds for use in various soft tissue repair applications and for the production of replacement tissue heart valves. The ADAPT[®] technology is used to process xenograft tissues to produce unique implantable tissue scaffolds that are compatible with the human body. The technology has a number of advantages over current tissue treatment processes on the market, most notably the reduction of calcification post implantation and has the potential to replace many of the products that surgeons currently use for soft tissue repair.

* Körbling&Estrov, 2003. Adult Stem Cells for Tissue Repair — A New Therapeutic Concept? NEJM Volume 349:570-582, August 7, 2003, Number 6